Sarah McGill is Senior Director and Head Global Access Product Strategy for Roche. Sarah joined Roche in 2006 and has held a variety of marketing and market access leadership positions across the pharmaceutical division. She is responsible for global access strategies across the Roche portfolio including support for lifecycle decisions, regulatory and HTA approvals, pricing, and reimbursement. Sarah’s team leads Roche’s policy engagement on AMR via IFPMA and EFPIA. Roche’s commitment to combat AMR and achieve a new Platinum Age for antibiotics R&D is underpinned by substantial investment in the discovery and development of novel antibiotics and the development of diagnostic assays to rapidly identify the type of drug-resistance bacteria responsible for infection. Roche is proud to join together with industry partners to support AMR Action Fund – a collective venture organized by IFPMA that will contribute more than $1 billion towards novel antibiotic development and support advocacy for a robust and sustainable pipeline of new antibiotics to fight drug-resistant infections.